BD Hit with $175M SEC Penalty for Misleading Investors

The SEC is leveling up its game, rolling out plans to modernize filings under the Securities Exchange Act of 1934. By 2028, compliance will (hopefully) feel less like pulling teeth. But while the SEC is looking forward, some companies are still grappling with their past—like Becton Dickinson (BD). BD, a medical device giant out of New Jersey, hit a major snag with its Alaris infusion pump. This isn’t just a footnote—it’s the pump responsible for about 10% of the company’s profits, acquired back in 2015 when BD bought CareFusion. Instead of being a steady moneymaker, though, Alaris turned into a full-blown compliance disaster, costing the company $175 million in penalties and a bruised reputation. 

37 Oopsies and a $175M Uh-Oh

Here’s the rundown: Back in 2016, BD realized the Alaris pump’s software changes needed FDA clearance. Did they hit pause to fix things? Nope. They kept selling it anyway, rolling the dice with compliance and patient safety. By 2019, the pump’s problems had snowballed into 37 critical software flaws—we’re talking glitches like infusion delays and failed low-battery alarms. Yet instead of being upfront, BD told investors the pump was just getting “routine improvements.” Behind the scenes, though, the FDA was not buying it. They rejected BD’s request to keep selling the pump while working on fixes. So, what did BD do? They resumed sales in December 2019—with temporary patches and no FDA clearance.

When the FDA Said ‘Nope’ And BD Felt the Burn

In January 2020, the FDA found out BD had restarted sales and wasn’t thrilled. They called BD’s actions “misaligned with our previous conversations.” Translation: You didn’t listen, and now we have a problem. Finally, BD reinstated a full sales hold and admitted that revenue would take a hit. But here’s where it gets dicey—at the January 2020 shareholders meeting, BD still stuck to its overly rosy revenue forecast. By February, the jig was up. BD admitted sales were halted indefinitely, and the stock dropped 12%, leaving investors fuming. As one analyst put it, “10 days ago we heard everything in pumps was OK… I’m stunned and have a lot of angry people with pitchforks.”

When 82% Went Too Far

It didn’t stop there. The SEC found BD had overstated its Q4 2019 operating income by a jaw-dropping 82% by failing to account for the costs of fixing Alaris. Basically, they made their books look a lot healthier than they actually were. Cue the SEC stepping in with charges for antifraud violations, reporting lapses, and poor disclosure controls. Along with the $175 million settlement, BD is now bringing in a compliance consultant to clean house.

A Tale of Triumph and Trouble

While BD’s mishandling of Alaris drew significant regulatory scrutiny, it’s important to acknowledge the pump’s critical role in healthcare. The Alaris system has been a mainstay in hospitals, safely delivering fluids, medications, and blood to patients for years. During the COVID-19 pandemic, it played an essential role in patient care despite its software challenges. Following a lengthy process, BD secured FDA clearance for the updated Alaris system in July 2023 and has since committed to updating its fleet of devices.

Transparency Isn’t Optional!

BD’s saga is a wake-up call: Short-term fixes and half-truths might save face for a while, but the long-term fallout—financial and reputational—can be brutal. Or, as SEC Acting Enforcement Director Sanjay Wadhwa said: “Public companies have a fundamental duty to accurately disclose material business risks and should expect to be held accountable when they fall short.” The SEC’s modernization efforts are a sign that compliance is getting smarter and stricter. Companies that play it straight will thrive. Those that don’t? Well, they’ll be joining BD in the penalty box.